NCT04670081View on ClinicalTrials.gov

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression

PHASE2CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

June 10, 2021

Primary Completion Date

February 27, 2024

Study Completion Date

December 11, 2024

Conditions
Treatment-resistant Depression
Interventions
DRUG

Psilocybin

25 mg, p.o.

DRUG

Psilocybin

5 mg, p.o.

DRUG

Nicotinamide

100 mg, p.o.

Trial Locations (2)

10117

Charité Berlin, Campus Mitte, Department of Psychiatry and Psychotherapy, Berlin

68159

Central Institute of Mental Health (CIMH), Mannheim

All Listed Sponsors
collaborator

Charite University, Berlin, Germany

OTHER

collaborator

MIND Foundation gGmbH

UNKNOWN

collaborator

German Federal Ministry of Education and Research

OTHER_GOV

collaborator

Usona Institute

OTHER

lead

Central Institute of Mental Health, Mannheim

OTHER